Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
about
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system.Rituximab for Rheumatoid Arthritis.Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers.High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective studyMechanism by which HLA-DR4 regulates sex-bias of arthritis in humanized mice.Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy.Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment.BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy.Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response.Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection.Addition of an indoleamine 2,3,-dioxygenase inhibitor to B cell-depletion therapy blocks autoreactive B cell activation and recurrence of arthritis in K/BxN mice.Advances in human B cell phenotypic profiling.Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.Rheumatoid factor B cell memory leads to rapid, switched antibody-forming cell responses.Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis.Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical responseRepeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD miceA perspective on B-cell-targeting therapy for SLE.B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis.B cells in the pathogenesis and treatment of rheumatoid arthritis.Anticytokine therapy in systemic lupus erythematosus.Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis.To B or not to B the conductor of rheumatoid arthritis orchestra.B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies.B cells and progressive multifocal leukoencephalopathy: search for the missing linkCytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases.Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.Update on the use of rituximab for intractable rheumatoid arthritis.Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients.
P2860
Q27691388-AFFF865E-608D-47FE-BECE-857C7D75FE2DQ27692640-698AE00B-C90C-4355-8EE2-275A12437361Q28080246-36589133-4B50-4DE6-94FC-65566E73C0D5Q33418352-F5EE52AC-82FC-4FF3-9ADA-E4A29DB9EBBDQ33616360-FE1416DF-8FAA-4A11-A5D3-2B80EF6E4051Q33765931-696FE940-0146-409F-AA6E-3FDDC6546B4EQ33886419-DE9B9741-F7A2-45BE-A98A-08DE3434759CQ33971785-E805F322-080C-4B97-A65B-ABF5111AFF82Q34110804-35016B99-86C7-4BC4-A2DB-07A07C7C7BC8Q34117122-CD29307C-5840-4F94-B64B-D789C1F3EC85Q34245983-C1DE2322-646F-40F3-8022-A83E2B9D0C53Q34362660-C71DB408-4EE8-481E-A0B0-BFD71CBF2F15Q34656882-8982AD31-D17F-40D3-AA5F-5D4D8576B82EQ35654669-EB52A740-F23D-4EB3-9B43-C256A22794ABQ35953366-0EFAE6F5-44B9-47F9-97D8-ED8563C5C945Q35957506-F7A67938-704D-4435-B8FE-8F6F442643BAQ36307080-E1A63404-A9B3-4B86-8D00-2E1E67B80005Q36484465-3EF0E721-3CBF-4BB4-916E-90EEFF02005AQ36625438-4EC794ED-7BA3-4DC5-A954-48884301F2BAQ36652772-3CD64F3B-6FD2-4DF7-8B61-C9FE28250533Q37270745-3C65B4AB-C85D-4446-8BBA-737B176A6EFFQ37350931-1230946D-603C-4B4E-BAFA-FF9ED8C5F00FQ37350960-8BB6CEC4-1096-4511-ABAE-8732B0493E82Q37377989-5C4594CE-2A31-4F28-B079-22083676206FQ37388213-A8B56A40-A6AD-472D-8318-BB55B7AE81BDQ37490637-DB6327FB-97A9-483A-A0A4-136684DF92BFQ37577571-BE2C20C7-DCA5-434A-A71A-DE30EAF5A86EQ37586921-CDF5B7F6-488C-4469-8D8D-47C8EF3BB80EQ37678888-6BE7211F-0E75-4F7C-ACFC-75D38D407996Q37800306-FFA0553B-1B6D-45CA-A435-B4FFAB735C10Q37826195-50512D22-1AD8-44D8-B59E-E5B14E930DECQ38020364-36B4E36B-6454-420F-872F-71FF5FD0519AQ38097170-EE290370-62CD-4E5F-BCD3-12531BB642E5Q38515349-26799F02-F6D4-4688-9AD2-11D41157B181Q38673420-44B6648E-9FFD-448D-80B4-DE3AC7BEDB5AQ38676903-6B2D352B-4B5E-4965-8FA8-D69AFBB999C5Q38690022-CA5AEEB5-DE13-44A5-87B8-A4A2F9EF4B13Q38979169-D3B0434D-7701-4EB2-87BA-19F0BD3A7D6DQ38993240-3AD00CF9-AF0A-4208-9614-BA1DA4EA67BFQ39453651-35F88452-1E4E-425E-9C0F-7263FEA56B51
P2860
Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Anti-CD20 therapy in patients ...... tion after repeated treatment.
@en
Anti-CD20 therapy in patients ...... tion after repeated treatment.
@nl
type
label
Anti-CD20 therapy in patients ...... tion after repeated treatment.
@en
Anti-CD20 therapy in patients ...... tion after repeated treatment.
@nl
prefLabel
Anti-CD20 therapy in patients ...... tion after repeated treatment.
@en
Anti-CD20 therapy in patients ...... tion after repeated treatment.
@nl
P356
P1476
Anti-CD20 therapy in patients ...... tion after repeated treatment.
@en
P2093
Petra Roll
Thomas Dörner
P2860
P304
P356
10.1002/ART.23473
P577
2008-06-01T00:00:00Z